Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $12.47 per share for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-11-05
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $11.01, a 26.60% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $15.00, a 13.34% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $17.31, a 1379.49% increase year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2018-03-31 was $1.17.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $12.83, a 21.53% decline from fiscal 2019.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $16.35, a 250.86% increase from fiscal 2018.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $4.66, a 448.24% increase from fiscal 2017.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $0.85, a 97.67% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2021-09-30 | $12.47 10-Q · filed 2021-11-05 | |||
| 2021-06-30 | $11.31 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $11.01 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $12.83 10-K · filed 2021-03-30 | |||
| 2020-09-30 | $13.55 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $14.37 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $15.00 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $16.35 10-K · filed 2021-03-30 | |||
| 2019-09-30 | $16.61 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | $16.95 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $17.31 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $4.66 10-K · filed 2021-03-30 | |||
| 2018-09-30 | $4.39 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | $4.02 10-Q · filed 2019-08-13 | |||
| 2018-03-31 | $1.17 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | $0.85 10-K · filed 2020-03-09 | |||
| 2017-09-30 | $0.64 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | $0.44 10-Q · filed 2018-08-30 | |||
| 2016-12-31 | $0.43 10-K · filed 2019-03-13 |